{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:17Z","timestamp":1791300497222,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ejim.2012.01.004","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T12:05:42Z","timestamp":1328357142000},"page":"317-324","source":"Crossref","is-referenced-by-count":120,"title":["Statin induced myotoxicity"],"prefix":"10.1016","volume":"23","author":[{"given":"Sivakumar","family":"Sathasivam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2012.01.004_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.01.004_bb0010","doi-asserted-by":"crossref","first-page":"a2286","DOI":"10.1136\/bmj.a2286","article-title":"Statin induced myopathy","volume":"337","author":"Sathasivam","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2012.01.004_bb0015","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.01.004_bb0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0025","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2012.01.004_bb0030","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1001\/jama.290.17.2243","article-title":"Expanding statin use to help more at-risk patients is causing financial heartburn","volume":"290","author":"Mitka","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2012.01.004_bb0035","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.01.004_bb0040","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2014 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0050","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0055","unstructured":"Rallidis L, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol in press [Electronic publication ahead of print]."},{"key":"10.1016\/j.ejim.2012.01.004_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2012.01.004_bb0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ejim.2012.01.004_bb0070","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.lpm.2011.01.005","article-title":"Pathophysiology of inflammatory and autoimmune myopathies","volume":"40","author":"Dalakas","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0075","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2012.01.004_bb0080","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2012.01.004_bb0085","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1592\/phco.22.17.1524.34130","article-title":"Etiology and frequency of rhabdomyolysis","volume":"22","author":"Black","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejim.2012.01.004_bb0090","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis","volume":"119","author":"Antons","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0095","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy","volume":"291","author":"Dirks","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2012.01.004_bb0105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.RES.83.5.490","article-title":"3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture","volume":"83","author":"Guijarro","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2012.01.004_bb0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10623329709079868","article-title":"Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin","volume":"5","author":"Morita","year":"1997","journal-title":"Endothelium"},{"key":"10.1016\/j.ejim.2012.01.004_bb0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2012.01.004_bb0130","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0135","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.amjcard.2007.12.005","article-title":"Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?","volume":"101","author":"Chatzizisis","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0150","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.ejim.2012.01.004_bb0155","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1586\/14779072.6.7.955","article-title":"Clinical characterization and molecular mechanisms of statin myopathy","volume":"6","author":"Toth","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejim.2012.01.004_bb0165","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.1991.00400080147030","article-title":"Lovastatin induced lupus erythematosus","volume":"151","author":"Ahmad","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0170","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(05)61628-5","article-title":"Polymyositis associated with simvastatin","volume":"349","author":"Giordano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2012.01.004_bb0175","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(02)09846-X","article-title":"Statins, fibrates, and ocular myasthenia","volume":"360","author":"Parmar","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2012.01.004_bb0180","doi-asserted-by":"crossref","first-page":"II15","DOI":"10.1161\/01.CIR.0000129502.10459.fe","article-title":"Statins as immunomodulatory agents","volume":"109","author":"Mach","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.01.004_bb0185","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1568-9972(03)00049-1","article-title":"Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins","volume":"2","author":"Kwak","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2012.01.004_bb0190","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2012.01.004_bb0195","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jcp.21810","article-title":"3-Hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation","volume":"220","author":"Martini","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11910-011-0232-9","article-title":"Update on toxic myopathies","volume":"12","author":"Mastaglia","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ejim.2012.01.004_bb0205","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0210","unstructured":"Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects. Arthritis Care Res (Hoboken) in press [Electronic publication ahead of print]."},{"key":"10.1016\/j.ejim.2012.01.004_bb0215","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ejim.2012.01.004_bb0220","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0225","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2007.01.067","article-title":"Safety of aggressive lipid management","volume":"49","author":"Davidson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0230","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14740330903188413","article-title":"Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety","volume":"8","author":"Kulik","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejim.2012.01.004_bb0235","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.archger.2009.09.042","article-title":"Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins","volume":"51","author":"Desai","year":"2010","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.ejim.2012.01.004_bb0240","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3949\/ccjm.76.s4.13","article-title":"Statins and noncardiac surgery: current evidence and practical considerations","volume":"76","author":"Poldermans","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2012.01.004_bb0250","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0255","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2012.01.004_bb0260","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0265","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0270","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2014 a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0275","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2012.01.004_bb0285","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","article-title":"Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin","volume":"55","author":"Zuccaro","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2012.01.004_bb0290","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ejim.2012.01.004_bb0295","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case\u2013control study","volume":"211","author":"Puccetti","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2012.01.004_bb0300","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2012.01.004_bb0305","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mus.22115","article-title":"Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional function of EYS","volume":"44","author":"Isackson","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2012.01.004_bb0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2012.01.004_bb0315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2008.03448.x","article-title":"Vitamin D deficiency \u2014 a novel mechanism of statin-induced myalgia?","volume":"71","author":"Lee","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2012.01.004_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin levels (<32ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.ejim.2012.01.004_bb0325","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1185\/03007995.2011.598144","article-title":"Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance","volume":"27","author":"Glueck","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2012.01.004_bb0330","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/15216540600871100","article-title":"Differential gene expression in skeletal muscle of rats with vitamin E deficiency","volume":"58","author":"Nier","year":"2006","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejim.2012.01.004_bb0335","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.mehy.2009.10.031","article-title":"Do statins cause myopathy by lowering vitamin E levels?","volume":"74","author":"Galli","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ejim.2012.01.004_bb0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0345","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/WCO.0b013e32833045a0","article-title":"Agents and mechanisms of toxic myopathy","volume":"22","author":"Kuncl","year":"2009","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0350","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00498250802585539","article-title":"Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy","volume":"39","author":"Sidaway","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejim.2012.01.004_bb0355","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","article-title":"Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy","volume":"29","author":"Silva","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0360","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0365","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/CRD.0b013e3181903b7f","article-title":"Antiretroviral and statin drug\u2013drug interactions","volume":"17","author":"Ray","year":"2009","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.ejim.2012.01.004_bb0370","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.amjcard.2005.12.007","article-title":"Statin safety and drug interactions: clinical implications","volume":"97","author":"Bottorff","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0375","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1185\/03007995.2011.589433","article-title":"Drug\u2013drug interactions with statins: will pitavastatin overcome the statins' Achilles heel?","volume":"27","author":"Corsini","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2012.01.004_bb0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-004-9011-5","article-title":"Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes","volume":"22","author":"Prueksaritanont","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.ejim.2012.01.004_bb0385","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/00498250601188808","article-title":"Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans","volume":"37","author":"Nakagomi-Hagihara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejim.2012.01.004_bb0390","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.01.004_bb0395","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1586\/17512433.1.1.105","article-title":"Drug\u2013drug interaction with statins","volume":"1","author":"Corsini","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0400","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0405","series-title":"ZOCOR prescribing information","author":"Merck and Company","year":"2011"},{"key":"10.1016\/j.ejim.2012.01.004_bb0410","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2005.08.038","article-title":"Striated muscle safety of ezetimibe\/simvastatin (Vytorin)","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0415","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0420","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"National Lipid Association Statin Safety Assessment Task Force: final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0425","first-page":"7","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial","volume":"260","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2012.01.004_bb0430","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0009-8981(74)90239-3","article-title":"Black\u2013white differences in serum creatine phosphokinase (CPK) activity","volume":"54","author":"Meltzer","year":"1974","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejim.2012.01.004_bb0435","series-title":"Muscular dystrophy \u2014 advances and new trends","first-page":"3","article-title":"Approaches to the membrane theory of Duchenne muscular dystrophy","author":"Rowland","year":"1980"},{"key":"10.1016\/j.ejim.2012.01.004_bb0440","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bmb\/ldm014","article-title":"Creatine kinase monitoring in sport medicine","volume":"81\u20132","author":"Brancaccio","year":"2007","journal-title":"Br Med Bull"},{"key":"10.1016\/j.ejim.2012.01.004_bb0445","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.metabol.2008.09.019","article-title":"Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?","volume":"58","author":"Glueck","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2012.01.004_bb0450","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2012.01.004_bb0455","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0460","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2009-2689","article-title":"Approach to the patient who is intolerant of statin therapy","volume":"95","author":"Eckel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2012.01.004_bb0465","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0470","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11910-008-0011-4","article-title":"Statin myopathy","volume":"8","author":"Radcliffe","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ejim.2012.01.004_bb0475","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0480","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","article-title":"Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy","volume":"250","author":"Bronner","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0485","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-141-8-200410190-00021","article-title":"Ezetimibe and statin-associated myopathy","volume":"141","author":"Phillips","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0490","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2165\/10898610-000000000-00000","article-title":"Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs","volume":"70","author":"Toth","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2012.01.004_bb0495","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/HJR.0b013e32801da137","article-title":"Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients","volume":"14","author":"Huang","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.ejim.2012.01.004_bb0500","doi-asserted-by":"crossref","first-page":"W147","DOI":"10.7326\/0003-4819-150-12-200906160-00006","article-title":"Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial","volume":"150","author":"Becker","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2012.01.004_bb0505","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1017\/S0317167100007514","article-title":"A neuromuscular approach to statin-related myotoxicity","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ejim.2012.01.004_bb0510","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0515","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.01.004_bb0520","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11940-011-0119-8","article-title":"Immunotherapy of inflammatory myopathies: practical approach and future prospects","volume":"13","author":"Dalakas","year":"2011","journal-title":"Curr Treat Options Neurol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T18:44:03Z","timestamp":1593629043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620512000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0953620512000271"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2012.01.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}